
MS and Demyelinating Disorders
Latest News


Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis

Divozilimab Cuts Relapse Risk at 1 Year in Phase 3 AQUARELLE Trial of NMOSD
Video Series

Latest Videos
Shorts










Podcasts
CME Content
More News

Here's some of what is coming soon to NeurologyLive® this week.

Ocrelizumab demonstrated noninferiority to fingolimod for relapse control but displayed greater reductions in MRI lesion activity among pediatric patients with relapsing-remitting multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

To close the series, Marisa McGinley, DO, presents her team’s model for predicting the risk of stopping MS therapy. Rebecca Cebull, CNP, and Robert Bermel, MD, explain why concrete, individualized risk data could change how patients and clinicians make treatment decisions.

Robert Bermel, MD, explains why progression independent of relapse activity (PIRA) is still identified only after the fact. Marisa McGinley, DO, and Rebecca Cebull, CNP, outline what clinicians can do today while targeted therapies remain on the horizon.

Pharmacogenomics plays a limited role in MS care today. Marisa McGinley, DO; Rebecca Cebull, CNP; and Robert Bermel, MD, discuss why, and how multidimensional biological profiling could one day guide therapy selection.

Here's some of what is coming soon to NeurologyLive® this week.

Neurologists Robert Bermel, MD; Rebecca Cebull, CNP; and Marisa McGinley, DO, discuss where serum neurofilament light and GFAP fit into MS care today and why the field is still waiting on a biomarker that captures progression.

Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.

FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
The FDA accepted fenebrutinib's new drug application under priority review for relapsing and primary progressive MS, based on 3 phase 3 trials comparing the BTK inhibitor with teriflunomide and ocrelizumab.

Here's some of what is coming soon to NeurologyLive® this week.

MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]

The positive opinion for intravenous ocrelizumab was supported by phase 3 OPERETTA 2 findings demonstrating noninferior relapse control and superior suppression of MRI-detected brain lesions compared with fingolimod in pediatric patients with relapsing MS.

An ACT–based group intervention did not significantly improve resilience at 3 months in patients with MS but was associated with improvements in anxiety, well-being, psychological flexibility, and health-related quality of life.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.

A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.

The FDA clearance allows AbelZeta to study bispecific CAR T-cell therapy C-CAR168 in refractory progressive multiple sclerosis.























